A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 115
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LND
Long Form : lonidamine
No. Year Title Co-occurring Abbreviation
2020 In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosussensu stricto and Echinococcus multilocularis. 6-AN, s. s
2020 Multi-responsive albumin-lonidamine conjugated hybridized gold nanoparticle as a combined photothermal-chemotherapy for synergistic tumor ablation. GNP
2019 Antitumor Effect of Lonidamine-Polypeptide-Peptide Nanoparticles in Breast Cancer Models. NPs
2019 Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis. CIA, OA, RA
2019 Optical Redox Imaging of Lonidamine Treatment Response of Melanoma Cells and Xenografts. Fp, ORI
2019 Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Mito-LND
2018 Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin. DOX, MRS
2018 Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria. ROS
2018 Negatively charged polypeptide-peptide nanoparticles showing efficient drug delivery to the mitochondria. NPs
10  2017 Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. CTRL, TMZ
11  2017 Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy. DTX, PEG-b-pAsp-b-pTyr, ROS
12  2017 Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat in colon cancer. DON
13  2017 Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance. DOX, NPs, TPP
14  2017 Targeting hexokinase II as a possible therapy for cholangiocarcinoma. CCA, OV
15  2016 Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. SF
16  2016 In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles. siRNA, TUNEL
17  2016 Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine. ---
18  2016 Mechanism of antineoplastic activity of lonidamine. MCT, MPC
19  2016 Role of Vitamin C in Cardioprotection of Ischemia/Reperfusion Injury by Activation of Mitochondrial KATP Channel. 5-HD, GSK, I/R, mitoKATP, mPTP, OGD/R, PI3K, VC
20  2016 The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. CHC, MCT, MPC
21  2015 Imaging chemical exchange saturation transfer (CEST) effects following tumor-selective acidification using lonidamine. AACID, CEST, GBM
22  2015 Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine. CP, PPF, TCPL, TPP
23  2015 Pre-treatment of a single high-dose of atorvastatin provided cardioprotection in different ischaemia/reperfusion models via activating mitochondrial KATP channel. 5-HD, ATOR, I/R, IPC, mitoKATP channels, mPTP, OGD/R, PCI
24  2015 Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. HA, MDR, P-gp, PTX
25  2015 The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. ---
26  2014 The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria. 3-BP
27  2014 Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH. BCECF, HSPs, MCT
28  2013 Male contraceptive Adjudin is a potential anti-cancer drug. ---
29  2011 Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. a-Cinn, HK I, HMECs, TAM
30  2010 AF-2364 is a prospective spermicide candidate. MPT
31  2009 Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. 2-DG, 3-BrPA, ALL
32  2009 Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy. 2-DG
33  2008 Glycosyl and polyalcoholic prodrugs of lonidamine. ---
34  2008 Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine. DMSO, TMZ
35  2007 Immunohistochemical profile of some neurotransmitters and neurotrophins in the seminiferous tubules of rats treated by lonidamine. NGF, NTs
36  2007 Lonidamine affects testicular steroid hormones in immature mice. A-dione, PND28
37  2005 Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH. BPH, IPSS, PSA, PV, PVR, TRUS
38  2005 Long-term effects of lonidamine on mouse testes. FCM
39  2005 Lonidamine transiently affects spermatogenesis in pubertal CD1 mice. PND
40  2005 The development of lonidamine for benign prostatic hyperplasia and other indications. BPH
41  2004 Apoptosis of human melanoma cells by a combination of lonidamine and radiation. ---
42  2004 Lonidamine causes inhibition of angiogenesis-related endothelial cell functions. ---
43  2003 Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. BC, DFS, EC, G-CSF, OS
44  2003 Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. GBM
45  2003 Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells. HCC, SRB
46  2002 Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. DOX
47  2002 Recent studies on lonidamine, the lead compound of the antispermatogenic indazol-carboxylic acids. ---
48  2002 Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. EPI
49  2001 Effect of lonidamine on alpha2-macroglobulin, hemopexin and alpha1-antitrypsin in the rat testis and epididymis. alpha 2M, alpha1-AT, APP, HPX
50  2001 Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. CI, i.v, OS, p.o, PFS
51  2000 Effects of lonidamine on testicular and epididymal proteins in the rat. ---
52  2000 Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. ---
53  2000 FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. EPI, i.v, MMC
54  2000 Lonidamine cytotoxicity: involvement of the lysosomal compartment. ---
55  2000 Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy. DWMRS
56  1999 bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. ADR
57  1999 Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. ---
58  1998 Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. DOX, MDR
59  1998 Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. TX
60  1998 Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification. HK, MRS, PCr, Pi, PPP
61  1998 Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. DOX
62  1997 Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). EPI
63  1997 Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. 5-FU, DX, MMC, MX, TX
64  1997 Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies. 2-DG, ADR, MDR, NMR
65  1997 Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. CDDP, EPI
66  1997 Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. CDDP, CI, CR, PR
67  1997 Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect. SO 6
68  1997 Schedule-dependent modulation of idarubicin cytotoxicity by lonidamine in human lymphoma cell lines. ATRA, DX, IDA
69  1997 Study of the photochemical and phototoxic properties of lonidamine [1-(2,4-dichlorobenzyl)-1H-indazol-3-carboxylic acid]. EAC
70  1997 The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. AO
71  1997 Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells. CARBO, PPC
72  1996 Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial. i.v, NSCLC
73  1996 Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. HPLC
74  1996 Effect of lonidamine on the mitochondrial potential in situ in Ehrlich ascites tumor cells. ---
75  1996 Effects of the inhibitors of energy metabolism, lonidamine and levamisole, on 5-aminolevulinic-acid-induced photochemotherapy. ALA, LEV, PCT, PpIX
76  1996 Enhancement of radiation response of prostatic carcinoma by lonidamine. ---
77  1996 Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. BC, EPI
78  1996 Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients. MMC
79  1995 Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. ADR
80  1995 Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas. EPI, PR
81  1995 In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line. SO 6
82  1995 Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. CR, EPI, i.v, PR
83  1995 Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II study. NSCLC, OR
84  1995 Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. NMR
85  1995 Mitochondria-bound hexokinase as target for therapy of malignant gliomas. HK, tHK
86  1994 A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG) CuLCaSG, DI, NSCLC
87  1994 In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. MMC
88  1994 Lonidamine-mediated respiratory changes in rat heart myocytes: a re-examination of the functional response of mitochondrial cytochrome c oxidase. ---
89  1994 Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. MTX
90  1994 The mode of action of the antitumor agent lonidamine involves calcium-associated actin filament rounding. ---
91  1993 A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. CL, DI, NSCLC
92  1993 Effect of lonidamine and rhein on the phosphorylation potential generated by respiring rat liver mitochondria. RH
93  1993 Invivo control of tumor-growth with the association of ionidamine with radiation and or hyperthermia. ---
94  1992 Invivo control of tumor-growth by lonidamine and radiations - influence of the timing and sequence of drug administration and irradiation treatment. ---
95  1992 The cytoskeleton as a subcellular target of the antineoplastic drug lonidamine. ---
96  1991 Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells. MPA, TAM
97  1991 Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart. DMSO, DX
98  1991 Radiation treatment plus CCNU plus the radiosensitizer lonidamine in malignant gliomas operated. CCNU, MST, RT
99  1991 The effect of lonidamine (LND) on radiation and thermal responses of human and rodent cell lines. PLD
100  1990 Antiproliferative effect of lonidamine on a human glioblastoma multiforme cell line. Li